louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06164782: A Survey on Psychosomatic Health Status of Chinese Population
Official title: A Survey on Psychosomatic Health Status of Chinese Population
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Psychosomatic; Disorder, Multiple
Well-Being, Psychological
Lead sponsor: Zhongda Hospital
Sponsor class: OTHER
First posted: 2023-12-11
Enrollment: 300000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: General population in China

Brief summary: A Survey on Psychosomatic Health Status of Chinese Population

Detailed description: This is a nationwide cross-sectional study to investigate psychosomatic symptoms among genral population in China. This study will also focus on the relationship between psychosomatic symptoms and functions and wellbeing.

Eligibility criteria: Inclusion Criteria:

* Age 18 years old and above;
* Able to complete the scale independently;
* Subjects read informed consent through online questionnaires and agreed to cooperate with relevant assessments.

Exclusion Criteria:

* Individuals with severe physical disease;
* Individuals with cognitive impairment;
* Individuals who cannot finish the online survay independently.

Primary outcomes:
measure: Psychosomatic health status
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Zhongda Hospital
name: Yonggui Yuan, Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT03884582: Observational Study Using the CoVa Monitoring System 3
Official title: Observational Study to Detect Cough and Wheeze Sounds Using the CoVa Monitoring System 3
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Healthy volunteers
Lead sponsor: Baxter Healthcare Corporation
Sponsor class: INDUSTRY
First posted: 2019-03-21
Enrollment: 14
Sex: ALL
Minimum age (years): 4
Maximum age (years): 17
Standard ages: CHILD
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy volunteers

Brief summary: Asthma is a complex and chronic inflammatory disorder which is associated with reversible airway obstruction and bronchial hyperresponsiveness. It is one of the most prevalent chronic diseases in children and prevalence further increases worldwide. Typical symptoms of asthma are breathlessness, cough, wheezing and chest tightness. These symptoms are particularly prevalent at night-time. Understanding and tracking these symptoms can lead to better management of asthma.

Auscultation using a stethoscope is standard clinical practice, however there is currently no available solution to detect respiratory sounds throughout the day and night.

The aim of this study is to investigate the feasibility of detecting respiratory sounds in healthy children with the CoVa patch.


Eligibility criteria: Inclusion Criteria:

* Participant is between the ages of 4 - 17 years old at the time of consent
* Participant and/or family member/carer willing to give written consent
* Participant and/or family member/carer who can read and comprehend english

Exclusion Criteria:

* Subject believed to be unsuitable for inclusion by the Principle Investigator
* Subject is pregnant at time of consent
* Subject is currently enrolled in another medical study

Primary outcomes:
measure: Ability to detect simulated respiratory sounds including coughing and wheezing or identify subjects which have asthma related respiratory issues
timeFrame: 2 Weeks
Secondary outcomes:
measure: Ability to detect simulated respiratory sounds including wheeze and cough during movement such a simulated situation of moving in bed.
timeFrame: 2 Weeks
Other outcomes:
Locations:
city: San Diego
country: United States
facility: toSense,Inc.
state: California
Study officials:
References:
Clinical trial NCT01682382: Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
Official title: Collection of Whole Blood Specimens and Buccal Swabs From Subjects Diagnosed With CNV AMD, Dry AMD, and Age-Matched Controls to Assess the Association of Genetic Variants in Complement Factor H With Risk of Progression to CNV.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Age-related Macular Degeneration
Choroidal Neovascular Age-related Macular Degeneration
Keywords: age-related macular degeneration
choroidal neovascular age-related macular degeneration
genetics
macular pigment optical density (MPOD)
Lead sponsor: Sequenom, Inc.
Sponsor class: INDUSTRY
First posted: 2012-09-10
Enrollment: 45
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Non-Hispanic Caucasian subjects 60 years of age and older diagnosed with either CNV or dry AMD and a cohort of age-matched controls

Brief summary: Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there is an association between genetics, MPOD and the risk of progression to wet AMD.


Eligibility criteria: Inclusion Criteria:

* subject is diagnosed with either CNV, dry AMD or is an age-matched control
* self reported as non-Hispanic Caucasian
* 60 years of age or older
* provides signed and dated informed consent
* agrees to provide 10 mL of whole blood and two buccal swabs

Exclusion Criteria:

* previous donation under this protocol

Primary outcomes:
measure: Association between a genetic variant in the CFH gene and risk of progression to CNV
timeFrame: Baseline
Secondary outcomes:
measure: Genetic correlation between MPOD and risk of progression to CNV
timeFrame: baseline
Other outcomes:
Locations:
city: Encinitas
country: United States
facility: Morris Eye Group
state: California
Study officials:
References:
Clinical trial NCT05785182: OCT in Open Fracture and Infected Fracture
Official title: Optical Coherence Tomography Imaging to Visualize Bacteria or Biofilm on Hardware, Bone and Soft Tissue in Open Fracture and Infected Fracture
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Trauma Injury
Trauma
Open Fracture
Fracture Infection
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
Collaborators: name: Dartmouth College
First posted: 2023-03-27
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients 18 years of age or older who present to DHMC (Lebanon) with open and infected fracture

Brief summary: This is a pilot prospective, observational study of patients with open or infected fracture evaluating the feasibility and acceptability of OCT, a light-based imaging modality that requires no drug or contrast agent.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Open fracture
* Fracture Related Infection

Exclusion Criteria:

* Metatarsal fractures

Primary outcomes:
measure: Feasibility and acceptability of OCT imaging
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: Dartmouth-Hitchcock Medical Center
name: Ida L Gitajn
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01437982: A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
Official title: A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Conjunctivitis, Seasonal Allergic
Conjunctivitis, Giant Papillary
Inflammation
Keywords: post-operative inflammation
conjunctivitis
safety
Seasonal allergic conjunctivitis
Giant papillary conjunctivitis
Lead sponsor: Bausch & Lomb Incorporated
Sponsor class: INDUSTRY
First posted: 2011-09-21
Enrollment: 140
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice

Detailed description: The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice after marketing authorization of Lotemax ophthalmic suspension 0.5%

Eligibility criteria: Inclusion Criteria:

* Subjects who have been treated with the study drug at least once and completed safety follow-up.
* Subjects who have been treated with the study drug at least once and completed the clinical efficacy assessment.

Exclusion Criteria:

* Subjects not treated with study drug at least once.

Primary outcomes:
measure: Safety
timeFrame: 4 years
Secondary outcomes:
measure: Seasonal Allergic Conjunctivitis
timeFrame: 4 years
measure: Giant Papillary Conjunctivitis
timeFrame: 4 years
measure: Post-operative inflammation
timeFrame: 4 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Bausch & Lomb Korea Ltd
Study officials:
affiliation: Valeant Pharmaceuticals
name: Binu Alexander, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05552482: Identifying Risk Factors (RF) for Early Haemodialysis Arteriovenous Fistula Failure (eAVFF)
Official title: Identification of Factors That Predict Early Haemodialysis Arteriovenous Fistula Failure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arteriovenous Fistula
Hemodialysis
End Stage Chronic Renal Failure
Lead sponsor: Centre Hospitalier Régional Metz-Thionville
Sponsor class: OTHER
First posted: 2022-09-23
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients (≥ 18 years) who had undergone distal (radioradial and radiocephalic) and proximal arteriovenous fistula (AVF) access creation surgery

Brief summary: Arteriovenous fisutla (AVF) is the vascular access of choice for hemodialysis but has a high early failure (eAVFF) rate. eAVFF can be defined as thrombosis/stenosis and Doppler ultrasound (DUS)-based failure-to-mature parameters such as postoperative blood flow (PostQa) \< 500 ml/min, AVF-vein diameter (PostVD) \< 5 mm, and AVF-vein depth (PostVDepth) ≥ 6 mm. We explored whether common risk factors for eAVFF could predict these eAVFF parameters and venous distensibility: the latter is largely overlooked as a potential eAVFF parameter.


Eligibility criteria: Inclusion Criteria:

* Adult patients (≥ 18 years)
* Patients who had undergone distal (radioradial and radiocephalic) or proximal arteriovenous fistula (AVF) access creation surgery between 2016 and 2021 at the CHR Metz-Thionville.
* Patients who underwent preoperative and postoperative Doppler ultrasound (DUS) ≤ 4 months after surgery.
* Patients with central venous catheter (CVC) at surgery

Exclusion Criteria:

* Patients using the fistula for intermittent plasmapheresis
* Patients with a radiobasilic AVF or arteriovenous graft

Primary outcomes:
measure: Identification of the pre/perioperative factors that predict early AVF failure (eAVFF)
timeFrame: up to 3 months after AVF creation
Secondary outcomes:
measure: Identification of the pre/perioperative factors that predict the early postoperative AVF blood flow (PostQa)
timeFrame: up to 3 months after AVF creation
measure: Identification of the pre/perioperative factors that predict the early postoperative venous internal diameter (PostVD)
timeFrame: up to 3 months after AVF creation
measure: Identification of the pre/perioperative factors that predict the early postoperative AVF stenosis and/or thrombosis
timeFrame: up to 3 months after AVF creation
measure: Identification of the pre/perioperative factors that predict the early postoperative skin to AVF distance
timeFrame: up to 3 months after AVF creation
Other outcomes:
Locations:
city: Metz
country: France
facility: CHR Metz-Thionville/Hopital de Mercy
Study officials:
affiliation: CHR Metz Thionville Hopital de Mercy
name: Zead TUBAIL, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00568282: Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Official title: Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2007-12-06
Enrollment: 219
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with advanced stage NSCLC who are either newly diagnosed, or who have evidence of disease progression.

Brief summary: The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Detailed description: The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.

Eligibility criteria: Inclusion Criteria:Inclusion Criteria:Inclusion Criteria (Cases):

1. Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC
2. Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection
3. ability to sign informed consent
4. at least 18 years of age

Inclusion Criteria (Controls):

1. no known prior or active malignancy
2. ability to sign informed consent
3. at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years

2. pregnant women

Primary outcomes:
measure: to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Heather A. Wakelee
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02665182: Up-positioning of the Testes as Supportive Therapy in Patients With Acute Orchitis
Official title: Up-positioning of the Testes as Supportive Therapy in Patients With Acute Orchitis - a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Orchitis
Testicular Diseases
Keywords: orchitis
testicular diseases
Lead sponsor: Medical University of Warsaw
Sponsor class: OTHER
First posted: 2016-01-27
Enrollment: 70
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single-blinded RCT evaluating the value of up-positioning of the testes as supportive therapy in patients receiving antimicrobial treatment due to acute bacterial orchitis.


Eligibility criteria: Inclusion Criteria:

* acute orchitis confirmed clinically and in scrotal ultrasound
* age \>=18 yrs

Exclusion Criteria:

* previous treatment of orchitis,
* need for exploration of the scrotum,
* need for hospitalization,
* physical and mental status not allowing for up-positioning of the testes during treatment

Primary outcomes:
measure: Time to alleviation of symptoms
timeFrame: 10 days
measure: Time to clinical resolution of local symptoms
timeFrame: 10 days
Secondary outcomes:
measure: Testicular pain
timeFrame: 10 days
measure: Testicular swelling
timeFrame: 10 days
measure: Testicular erythema
timeFrame: 10 days
measure: Scrotal pain intensity
timeFrame: 10 days
measure: Quality of life
timeFrame: 10 days
measure: Body temperature
timeFrame: 10 days
measure: Heart rate
timeFrame: 10 days
measure: Duration of up-positioning of testes per day
timeFrame: 10 days
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Sławomir Poletajew
Study officials:
affiliation: Medical University of Warsaw
name: Sławomir Poletajew, MD PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00959582: Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
Official title: A Multicenter Trial to Measure Early Patterns of Change in [18F]-Fluorodeoxyglucose Uptake by PET/CT in Relapsed Ovarian Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
Keywords: Relapsed ovarian cancer
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-08-14
Enrollment: 42
Sex: FEMALE
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study will characterize FDG-PET (18F-Fluorodeoxyglucose-Positron Emission Tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based therapy.


Eligibility criteria: Inclusion Criteria:

* Patient has ovarian, primary peritoneal, or fallopian tube cancer
* Patient has first or subsequent relapse
* Patient has had at least on prior platinum-based treatment for ovarian cancer
* Patient is scheduled to receive treatment with carboplatin or cisplatin monotherapy or combination where one of the drugs is a platinum
* Patient is not pregnant

Exclusion Criteria:

* Patient has had abdominal surgery within the last 6 weeks
* Patient has life expectancy \< 6 months
* Patient has had radiotherapy to the abdomen or pelvis within the last 6 months
* Patient has poorly controlled diabetes

Primary outcomes:
measure: Proportion of patients with metabolic non-response assessed by FDG-PET standardized uptake value (SUV) 3 weeks and 6 weeks after starting platinum-based therapy
timeFrame: Baseline, Week 3, Week 6
measure: Progression free proportion
timeFrame: 40 Weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00565682: Pain Post Abdominal Laparoscopy Prevention With Arcoxia
Official title: Pain Post Abdominal Laparoscopy Prevention With Arcoxia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Laparoscopic Surgery for Appendicitis
Laparoscopic Surgery for Cholecystitis
Laparoscopic Surgery for Ovarian Cysts
Lead sponsor: Hospital Vozandez
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2007-11-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To test the analgesic efficacy of etoricoxib used before a surgical procedure compared to the already known effect when administered after such a procedure. Patient will be receiving either etoricoxib or the respective placebo one hour before surgery, then two hours after those receiving the active will receive placebo and those that received placebo will be given etoricoxib. Pain score measurements will be performed sequentially. Rescue medication will be available all the time.


Eligibility criteria: Inclusion Criteria:

* Voluntary acceptance to participate in the study and signed the informed consent form
* Age older than 18 years old and younger than 70 years
* Diagnosis of appendicitis, cholecystitis or ovarian cysts suitable of laparoscopic surgery

Exclusion Criteria:

* Age less than 18 years or older than 70 years.
* Laparoscopic procedures for diagnostic purposes.
* Current use of anticoagulants.
* Known hypersensitivity to etoricoxib or its components.
* History of a CABG or MI (less than 1 year)
* History of unstable angina (over the past six months).
* Current inflammatory bowel disease.
* Uncontrolled hypertension or heart failure
* Renal dysfunction/impairment (creatinine clearance \< 30ml/min)
* Cirrhosis or severe hepatic dysfunction
* Any degree of dehydration (mild to severe)

Primary outcomes:
measure: To measure the amount of rescue medication (opioid) needed to relief
timeFrame: Every hour after surgery
Secondary outcomes:
measure: To determine the overall analgesic effect using the visual analog scale (VAS)
timeFrame: Every hour after surgery
Other outcomes:
Locations:
Study officials:
affiliation: Hospital Vozandez
name: Eduardo Noboa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03432182: Body Movements Analysis During Sleep in Very Premature Infants
Official title: Characterization of Movements Occurring During Sleep in Very Premature Neonates: Relationship With Neurodevelopmental Outcome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep
Keywords: Premature infant
sleep state
body movement
neurodevelopmental outcome
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2018-02-14
Enrollment: 68
Sex: ALL
Minimum age (years): 10
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Sleep is a key factor for normal brain development of the newborn. However, it is poorly studied and little is known about its characterization, especially in premature infants. Body movements during sleep are easy to evaluate but studies on their relationship to normal sleep states are scarce and limited. This project aims to characterize body movements during sleep, assessed by electroencephalography, in very premature infants. Then, a correlation between body movements, sleep organization and neurodevelopmental outcome will be evaluated at 3 years of age.


Eligibility criteria: Inclusion Criteria:

* Infants born between 26 and 32 weeks gestation

Exclusion Criteria:

* Genetic abnormality
* Neurological pathology such as intraventricular hemorrhage \> grade 2
* Any medication know for altering electroencephalography recording

Primary outcomes:
measure: Body movements evaluation during sleep
timeFrame: 3 months
Secondary outcomes:
measure: Sleep states organization
timeFrame: 3 months
measure: Type of movements observed during sleep
timeFrame: 3 months
measure: Neurodevelopmental outcome
timeFrame: 3 years
Other outcomes:
Locations:
city: Nancy
country: France
facility: Maternity Hospital CHRU
Study officials:
References: